ak3280
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2019 (NCT03990688)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05434897 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2022 | Ark Biosciences Inc., Innovaderm, University of California, San Francisco |
| NCT05424887 | Phase 2 | Jul 31, 2022 | Ark Biosciences Inc., Innovaderm, University of California, San Francisco |
| NCT04926116 | Phase 1 | Jun 9, 2021 | Ark Biosciences Inc. |
| NCT03990688 | Phase 1 | Aug 31, 2019 | Ark Biosciences Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ark Biosciences Inc. | For profit | 4 | 4 | 2 | 2019 |
| Innovaderm | For profit | 2 | 0 | 1 | 2022 |
| University of California, San Francisco | Academic/Hospital | 2 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1